The usability of testing skin reaction applying skin prick tests with Comirnaty (Pfizer, USA) vaccine in detecting the risk of developing post-vaccination immediate hypersensitivity response (anaphylaxis) after administration of this vaccine

Ewelina Gulas; Andrzej Bant; Jerzy Kruszewski; Barbara Betiuk; Marek Niedoszytko; Andrzej Chciałowski

doi:10.5114/ada.2023.131860

eISSN: 2299-0046
ISSN: 1642-395X

Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii

Current issue Archive Manuscripts accepted About the journal Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

5/2023
vol. 40

Send email

Copy url:

abstract:

Original paper

The usability of testing skin reaction applying skin prick tests with Comirnaty (Pfizer, USA) vaccine in detecting the risk of developing post-vaccination immediate hypersensitivity response (anaphylaxis) after administration of this vaccine

Ewelina Gulas

¹

,

Andrzej Bant

¹

,

Jerzy Kruszewski

¹

,

Barbara Betiuk

²

,

Marek Niedoszytko

³

,

Andrzej Chciałowski

¹

Department of Infectious Diseases and Allergology, Military Institute of Medicine, National Research Institute, Warsaw, Poland
Vaccination Clinic of Military Instytute of Medicine, National Research Institute, Warsaw, Poland
Allergology Department, Medical University of Gdansk, Gdansk, Poland

Adv Dermatol Allergol 2023; XL (5): 655-660

DOI: https://doi.org/10.5114/ada.2023.131860

Online publish date: 2023/10/08

View full text Get citation

EndNote

Papers, Reference Manager, RefWorks, Zotero

AMA

Gulas E, Bant A, Kruszewski J, Betiuk B, Niedoszytko M, Chciałowski A. The usability of testing skin reaction applying skin prick tests with Comirnaty (Pfizer, USA) vaccine in detecting the risk of developing post-vaccination immediate hypersensitivity response (anaphylaxis) after administration of this vaccine. Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii. 2023;40(5):655-660. doi:10.5114/ada.2023.131860.

APA

Gulas, E., Bant, A., Kruszewski, J., Betiuk, B., Niedoszytko, M.,  & Chciałowski, A. (2023). The usability of testing skin reaction applying skin prick tests with Comirnaty (Pfizer, USA) vaccine in detecting the risk of developing post-vaccination immediate hypersensitivity response (anaphylaxis) after administration of this vaccine. Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii, 40(5), 655-660. https://doi.org/10.5114/ada.2023.131860

Chicago

Gulas, Ewelina, Andrzej Bant, Jerzy Kruszewski, Barbara Betiuk, Marek Niedoszytko,  and Andrzej Chciałowski. 2023. "The usability of testing skin reaction applying skin prick tests with Comirnaty (Pfizer, USA) vaccine in detecting the risk of developing post-vaccination immediate hypersensitivity response (anaphylaxis) after administration of this vaccine". Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii 40 (5): 655-660. doi:10.5114/ada.2023.131860.

Harvard

Gulas, E., Bant, A., Kruszewski, J., Betiuk, B., Niedoszytko, M.,  and Chciałowski, A. (2023). The usability of testing skin reaction applying skin prick tests with Comirnaty (Pfizer, USA) vaccine in detecting the risk of developing post-vaccination immediate hypersensitivity response (anaphylaxis) after administration of this vaccine. Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii, 40(5), pp.655-660. https://doi.org/10.5114/ada.2023.131860

MLA

Gulas, Ewelina et al. "The usability of testing skin reaction applying skin prick tests with Comirnaty (Pfizer, USA) vaccine in detecting the risk of developing post-vaccination immediate hypersensitivity response (anaphylaxis) after administration of this vaccine." Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii, vol. 40, no. 5, 2023, pp. 655-660. doi:10.5114/ada.2023.131860.

Vancouver

Gulas E, Bant A, Kruszewski J, Betiuk B, Niedoszytko M, Chciałowski A. The usability of testing skin reaction applying skin prick tests with Comirnaty (Pfizer, USA) vaccine in detecting the risk of developing post-vaccination immediate hypersensitivity response (anaphylaxis) after administration of this vaccine. Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii. 2023;40(5):655-660. doi:10.5114/ada.2023.131860.

Introduction:
COVID-19 vaccines became a relevant element of prevention during COVID-19 pandemic. It is worth highlighting the importance of severe allergic post-vaccination reactions.

Aim:
To evaluate the usability of skin reaction tests using skin prick tests with Comirnaty (Pfizer, USA) vaccine in risk detection of the post-vaccine immediate hypersensitivity reaction (anaphylaxis) after administration of this vaccine [PvIHR(A)].

Material and methods:
The analysis embraces 102 people, 85 women and 17 men with a history of immediate hypersensitivity (anaphylaxis) [IHR(A)]. Detailed medical history was collected and skin prick tests were made among participants. The positive and negative test results were illustrated in Figure 1.

Results:
As it stands in Table 1, considering all participants of the study, a positive result of the skin prick tests was obtained only in 2 cases, a negative result in 99 and 1 result was questionable. The two positive results were found in participants from a group with a previous PvIHR(A) in their past medical history and they decided not to get vaccinated. The one questionable result was of a person that had PvIHR(A) after administration of the first dose of Comirnaty vaccine (Pfizer, USA). This person decided to get vaccinated again and there was no PvIHR(A) observed.

Conclusions:
COVID-19 vaccination involves a low risk of anaphylaxis. Purposefulness of providing the skin prick tests using the mRNA vaccine is questionable, due to their low sensitivity and low specificity.

keywords:

The usability of testing skin reaction applying skin prick tests with Comirnaty (Pfizer, USA) vaccine in detecting the risk of developing post-vaccination immediate hypersensitivity response (anaphylaxis) after administration of this vaccine

Ewelina Gulas 1 , Andrzej Bant 1 , Jerzy Kruszewski 1 , Barbara Betiuk 2 , Marek Niedoszytko 3 , Andrzej Chciałowski 1

anaphylaxis, COVID-19, SARS-CoV-2, COVID-19 vaccination, mRNA vaccine

Ewelina Gulas

¹

,

Andrzej Bant

¹

,

Jerzy Kruszewski

¹

,

Barbara Betiuk

²

,

Marek Niedoszytko

³

,

Andrzej Chciałowski

¹